Aligos Therapeutics, Inc.
Nasdaq · CIK 0001799448 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$2.8M
Operating Income
$-26.9M
Net Income
$-23.0M
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $2.8M | - | - |
| Operating Income | $-26.9M | - | - |
| Net Income | $-23.0M | - | - |
| Eps Basic | -2.21 | - | - |
| Eps Diluted | -2.21 | - | - |
| Cash And Equivalents | $30.0M | - | - |
| Total Assets | $64.6M | - | - |
| Total Liabilities | $32.8M | - | - |
| Shareholders Equity | $31.8M | - | - |
| Operating Cash Flow | $-23.1M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Aligos Therapeutics, Inc. | 2026-05-07 | 0001193125-26-212001 |
| 10-K | Aligos Therapeutics, Inc. | 2026-03-05 | 0001193125-26-092614 |
| 10-Q | Aligos Therapeutics, Inc. | 2025-11-06 | 0001193125-25-268203 |
| 10-Q | Aligos Therapeutics, Inc. | 2025-08-06 | 0000950170-25-104042 |